3 aug 2016 we assessed patient-reported outcomes (pros) in patients with decompensated cirrhosis given a fixed-dose combination of sofosbuvir and; 8 apr 2015 ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated japanese; aliment pharmacol ther. 30 jan 2015 sofosbuvir (sof) in combination with ribavirin (rbv) for 12 or 24 weeks is the current standard of care for patients infected with hepatitis c virus; n engl j med. 300 mg with 100 mg ritonavir x 10 days given staggered from harvoni by 12 hours, 90/400 mg, atazanavir auc(tau) increased 43%, ledipasvir auc(tau); 17 nov 2015 to receive sofosbuvir;velpatasvir for 12 weeks (277 patients) or sofosbuvir; to those with standard treatment with sofosbuvir;ribavirin. 31 mar 2015 although sofosbuvir would not be able to increase amiodarone levels fast enough to explain the sudden bradycardia, the opposite could occur:; 15 nov 2016 treatment with ledipasvir;sofosbuvir for 12 or 24 weeks was the high efficacy observed with fixed-dose ledipasvir;sofosbuvir, even when; harvoni is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration. 4 jan 2016 sofosbuvir is a nucleotide analogue inhibitor of the hcv ns5b polymerase approved for the treatment of hcv in combination with a variety of; 12 weeks of sofosbuvir in combination with pegifn/rbv. 4 jun 2016 effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ ombitasvir and dasabuvir regimens for treatment of patients with; sofosbuvir (sovaldi()) is a nucleotide hepatitis c virus (hcv) ns5b polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to; hepatology.
